Eagle Health Investments LP Acquires Shares of 624,676 BioMarin Pharmaceutical Inc. $BMRN
Eagle Health Investments LP has acquired 624,676 shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, making it their fifth-largest holding. This acquisition, valued at approximately $35.7 million, contributes to institutional investors collectively owning 98.71% of BioMarin. The news follows BioMarin's agreement to acquire Alesta Therapeutics, boosting its rare-disease portfolio, and a "Moderate Buy" analyst consensus with an average price target of $88.83.
BIOMARIN PHARMACEUTICAL INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $98
BMO has initiated coverage on BioMarin Pharmaceutical Inc. (BMRN.O) with an "Outperform" rating. The firm has set a price target of $98 for the biotechnology company. This information was reported by Reuters.
BioMarin to acquire Alesta Therapeutics for up to $490 million
BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Alesta Therapeutics for up to $490 million. The acquisition involves an upfront cash payment of $275 million for Alesta's lead asset, ALE1, a therapy for hypophosphatasia, with potential additional milestone payments of up to $215 million. Existing Alesta shareholders will retain interests in a newly formed entity for non-ALE1 assets, and the transaction is expected to close in Q3 2026.
BioMarin initiated an outperform at BMO as Voxzogo erosion overstated
BMO Capital Markets initiated coverage of BioMarin Pharmaceutical (BMRN) with an "outperform" rating. The firm believes that investors are overstating the potential sales erosion of BioMarin's key treatment, Voxzogo, indicating a potential 46% upside. BioMarin's current trading valuation is also noted to be significantly lower than its peers.
H.C. Wainwright cuts BioMarin stock price target on acquisition costs
H.C. Wainwright has lowered its price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $59 from $60, maintaining a Neutral rating, due to costs associated with BioMarin's acquisition of Alesta. Despite this, the stock trades near its 52-week high, and InvestingPro suggests it is undervalued. The acquisition, valued at $275 million upfront with potential additional milestones, aims to secure ALE1, a clinical-stage asset for hypophosphatasia.
GSA Capital Partners LLP Invests $944,000 in BioMarin Pharmaceutical Inc. $BMRN
GSA Capital Partners LLP has invested $944,000 in BioMarin Pharmaceutical Inc. by acquiring 16,501 shares during the second quarter, making them a new institutional stakeholder. This move comes as other institutional investors have also adjusted their positions, and BioMarin continues to receive a "Moderate Buy" consensus rating from analysts with an average price target of $88.41. The company recently reported strong quarterly results, exceeding revenue and EPS expectations, and announced the acquisition of Alesta Therapeutics, strengthening its long-term growth outlook.
REG - RTW Biotech Opp. - BioMarin to acquire Alesta Therapeutics
RTW Biotech Opportunities Ltd ("RTW Bio") announced that BioMarin Pharmaceutical Inc. is set to acquire Alesta Therapeutics, a clinical-stage biotechnology company. The deal includes an upfront cash payment of $275 million for Alesta's lead asset, ALE1, which represents a 41% uplift to RTW Bio's carrying value, with potential for an additional $215 million in milestone payments. This marks the sixth acquisition from RTW Bio's portfolio in 2026, validating its strategy of investing in early-stage, differentiated science.
BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company
BioMarin Pharmaceutical is reportedly looking to acquire Dutch bone drug company Alesa Therapeutics for up to $490 million, including a $275 million upfront payment. This potential acquisition comes shortly after BioMarin decided to halt the late-stage development of another drug. The move is seen as an effort to spur growth for the company.
BioMarin to Acquire Alesta Therapeutics for Up to $490 Million
BioMarin Pharmaceutical Inc. is set to acquire Alesta Therapeutics for up to $490 million, securing Alesta's lead clinical program, ALE1, an oral therapy for hypophosphatasia (HPP). This acquisition, consisting of an upfront payment of $275 million and up to $215 million in milestones, will expand BioMarin's rare disease pipeline and skeletal conditions portfolio. Alesta will spin out its other assets and employees before the deal closes, making ALE1 the sole focus of the acquisition.
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351
This M&A roundup details several significant deals in the pharmaceutical sector, including LEO Pharma's acquisition of dersimelagon for rare skin diseases, BioMarin's purchase
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
BioMarin Pharmaceutical has acquired Alesta Therapeutics for an upfront payment of $275 million, with an additional $215 million in potential milestones. This acquisition aims to position BioMarin to compete with AstraZeneca in the rare bone disease market, specifically hypophosphatasia (HPP), with Alesta's oral drug candidate, ALE1. The deal allows BioMarin to target the adult HPP market, which is currently underserved by existing treatments, and strengthens its skeletal condition unit.
BioMarin stock surges on $275M Alesta acquisition deal
BioMarin Pharmaceutical Inc. announced its acquisition of Alesta Therapeutics for $275 million upfront, causing BioMarin's shares to rise by 4.7% in premarket trading. The deal grants BioMarin access to ALE1, an oral therapy for hypophosphatasia (HPP) currently in clinical trials, with potential additional payments up to $215 million. This acquisition is expected to make ALE1 the first oral treatment for HPP, a rare genetic bone disease, offering an alternative to existing injectable therapies.
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
BioMarin Pharmaceutical Inc. announced its definitive agreement to acquire Alesta Therapeutics, primarily for its lead clinical-stage asset, ALE1. ALE1 is a potential first oral therapy for hypophosphatasia (HPP), a rare genetic bone disease, and is currently in Phase 1/2a clinical trials. The acquisition involves an upfront payment of $275 million plus up to $215 million in milestone payments, with Alesta spinning out its non-ALE1 assets and transferring its employees to a new entity before the acquisition closes.
Rice Hall James & Associates LLC Makes New Investment in BioMarin Pharmaceutical Inc. $BMRN
Rice Hall James & Associates LLC has made a new investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), purchasing 248,224 shares valued at approximately $14.2 million. Institutional investors now own 98.71% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $88.45. BioMarin recently reported strong quarterly earnings, beating estimates with EPS of $1.20 and a 20% year-over-year revenue increase to $989.71 million.
Grandfield & Dodd LLC Takes $1.04 Million Position in BioMarin Pharmaceutical Inc. $BMRN
Grandfield & Dodd LLC has acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), purchasing 18,243 shares valued at approximately $1.04 million during the second quarter. This move comes as several other institutional investors have also adjusted their stakes in the biotechnology company. BioMarin Pharmaceutical recently reported strong quarterly earnings, beating analyst expectations, and has received a "Moderate Buy" consensus rating from analysts with an average price target of $88.45.
Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN
Persistent Asset Partners Ltd has made a new investment of $4.57 million in BioMarin Pharmaceutical Inc., acquiring 79,933 shares, which now constitutes 1.4% of its portfolio. BioMarin recently reported strong Q2 earnings, surpassing analyst estimates with $1.20 EPS and $989.71 million in revenue, and analysts maintain a "Moderate Buy" rating with an average target price of $88.00. The company focuses on developing therapies for rare genetic and metabolic diseases, with institutional investors holding a significant 98.71% of its stock.
Monaco Asset Management SAM Invests $10.58 Million in BioMarin Pharmaceutical Inc. $BMRN
Monaco Asset Management SAM has invested $10.58 million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), acquiring 184,937 shares, making it their eighth-largest holding. This investment comes as BioMarin reported strong quarterly earnings, beating analyst estimates with $1.20 EPS and a 20% revenue increase year-over-year. Analysts generally maintain a "Moderate Buy" rating for BMRN, with an average price target of $88.00.
BIOMARIN PHARMACEUTICAL INC. : PIPER SANDLER RAISES TARGET PRICE TO $88 FROM $82
Piper Sandler has increased its target price for BioMarin Pharmaceutical Inc. (BMRN.O) from $82 to $88. This adjustment reflects an updated outlook from the analytical firm regarding the biotechnology company's valuation. The news was reported by Reuters.
BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration
BioMarin Pharmaceutical (BMRN) saw its stock rise 5.6% after reporting Q2 2026 results, raising its full-year 2026 revenue guidance to US$3.88 billion–US$3.93 billion, and filing a US$719.24 million ESOP-related shelf registration. Despite higher revenue, net income was lower, and the company expects over half of its second-half revenue to come from the fourth quarter. This update provides investors with more information regarding BioMarin's cost structure, growth drivers, and capital plans, though concerns remain about rising costs, debt, and share dilution.
Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?
BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on VOXZOGO, and encourages further analysis of the company's fundamentals and potential warning signs.
Summit Global Investments Buys New Stake in BioMarin Pharmaceutical Inc. $BMRN
Summit Global Investments has acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), purchasing 32,667 shares valued at approximately $1.87 million during the second quarter. This move comes as institutional investors collectively own 98.71% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average price target of $88. BioMarin recently exceeded quarterly expectations, reporting $1.20 EPS against a $0.95 consensus and $989.71 million in revenue, a 20% year-over-year increase.
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
BioMarin Pharmaceutical (BMRN) is outperforming the Medical sector and its specific industry year-to-date, with a 15.3% return compared to the sector's 3%. The company holds a Zacks Rank #2 (Buy) due to improving analyst sentiment. Cardinal Health (CAH) is another medical stock showing strong performance within the sector.
Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries
This article from Zacks.com highlights five undervalued stocks worth buying in August, chosen based on their favorable price-to-book (P/B) ratios. The featured companies are BioMarin Pharmaceutical (BMRN), Invesco (IVZ), Centene Corporation (CNC), Hewlett Packard Enterprise (HPE), and Gibraltar Industries (ROCK). The piece explains the utility of the P/B ratio as a valuation tool for identifying potentially undervalued stocks.
BMRN vs. ILMN: Which Stock Is the Better Value Option?
This article evaluates BioMarin Pharmaceutical (BMRN) and Illumina (ILMN) as value stock options in the Medical - Biomedical and Genetics sector. Both companies currently hold a Zacks Rank #2 (Buy), indicating positive earnings outlooks. However, based on various valuation metrics such as P/E, PEG, and P/B ratios, BMRN appears to be the superior value option with a Value grade of B compared to ILMN's C.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts
Analysts have given BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) an average "Moderate Buy" rating, with a consensus 12-month price target of $88.00. The company recently reported strong quarterly results, with revenue up 20% year-over-year and raised its 2026 VOXZOGO revenue guidance to at least $1 billion. Despite positive regulatory progress for VOXZOGO and strong institutional investment, mixed analyst views and recent insider sales represent potential concerns.
Biomarin Pharmaceutical stock hits 52-week high at 66.28 USD
BioMarin Pharmaceutical (BMRN) stock reached a new 52-week high of $66.28, reflecting a 16.44% increase over the past year. InvestingPro analysis suggests the stock is undervalued with strong fundamentals, including 11.2% revenue growth. The company also reported impressive Q2 2026 results, exceeding Wall Street expectations, which led to raised price targets from analysts.
BioMarin presentation to stream live from Boston on Aug. 12
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00 AM ET in Boston. A live audio webcast and a limited-time archived replay will be available on the company's investor website. Following this announcement, BioMarin's stock (BMRN) gained 4.90%, showing a moderate positive market reaction.
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
BioMarin Pharmaceutical Inc. announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00 AM ET in Boston. An audio webcast of the presentation will be available live on the company's investor relations website, and an archived version will be accessible for a limited time following the conference. BioMarin is a global biotechnology company specializing in medicines for genetically defined rare diseases.
Canaccord raises BioMarin stock price target on revenue growth
Canaccord has increased its price target for BioMarin Pharmaceutical Inc. (BMRN) to $114 from $111, maintaining a Buy rating, following strong second-quarter 2026 earnings. The company's revenue growth was significantly boosted by the acquisition of GALAFOLD and POMBILITI + OPFOLDA, leading to raised fiscal 2026 guidance. BioMarin also reported positive developments in its drug pipeline, including progress with Voxzogo and BMN 820.
Pacer Advisors Inc. Sells 913,713 Shares of BioMarin Pharmaceutical Inc. $BMRN
Pacer Advisors Inc. significantly reduced its stake in BioMarin Pharmaceutical Inc. by 97.5% during the first quarter, selling over 913,000 shares. Despite this large institutional sale, other major investors increased their holdings, and BioMarin reported stronger-than-expected Q2 earnings and raised its 2026 guidance, though it faces a clinical development setback. The company maintains a "Moderate Buy" consensus from analysts, with a target price of $87.86.
BioMarin Pharmaceutical Inc. (BMRN.MX) Analyst insights, Price targets and Recommendations
This article provides an overview of recent analyst ratings for BioMarin Pharmaceutical Inc. (BMRN.MX), including upgrades, downgrades, and maintained ratings from various financial institutions. It lists the latest price targets and recommendations from firms like Morgan Stanley, Oppenheimer, and Citigroup, along with the dates of their assessments. The stock BMRN.MX is trading at 959.00 with 0.00% change.
BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Raised to $89.5, Implies 46% Upside
BioMarin Pharmaceutical Inc.'s average stock price target has been raised to $89.5 from $87.83 by 24 analysts, indicating a potential 46% upside based on the Aug. 6 closing price. The consensus rating from 29 analysts remains "Buy," with 22 Buys, 7 Holds, and no Sells. Forecasts for the stock range from $60 to $124 per share.
Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) News, Articles, Events & Latest Updates
BioMarin Pharmaceutical Inc. (BMRN) has reported strong Q2 2026 earnings, surpassing estimates in both revenue and profit, driven by significant sales growth and an increased 2026 outlook. The company also announced an early research collaboration with n-Lorem Foundation and the FDA's acceptance of its sNDA for full Voxzogo approval, with a decision expected by February 28, 2027.
Biomarin Pharma earnings beat by $0.25, revenue topped estimates
Biomarin Pharma (NASDAQ: BMRN) reported strong second-quarter results, beating analyst estimates for both earnings per share (EPS) and revenue. The company posted an EPS of $1.20, exceeding the $0.95 consensus, and revenue of $990 million, higher than the $939.37 million estimate. Its stock has shown positive performance, rising 13.67% over the last three months.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q2 revenue up, profit down after Amicus acquisition
BioMarin Pharmaceutical Inc. reported a significant increase in Q2 2026 total revenues to $989.7 million, up from $825.4 million in 2025, primarily due to strong performance from VOXZOGO, PALYNZIQ, and newly acquired products GALAFOLD and POMBILITI + OPFOLDA. Despite revenue growth, net income fell to $44.8 million from $240.5 million in the prior year, attributed to increased operating and financing costs following the $5.3 billion Amicus acquisition, including intangible asset amortization and interest expenses. The acquisition introduced substantial debt but also expanded BioMarin's rare disease portfolio with new therapies and pipeline assets.
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q2 Adjusted EPS $1.20 per Share, vs. FactSet Est of $0.95
BioMarin Pharmaceutical Inc. (BMRN) reported Q2 adjusted EPS of $1.20 per share, surpassing the FactSet estimate of $0.95. The company also announced Q2 revenue of $990.0 million, exceeding the FactSet estimate of $932.0 million, and provided updated earnings guidance for the full year 2026. This news comes alongside other recent company updates, including FDA acceptance for Voxzogo's full approval and analyst rating adjustments.
BioMarin earnings on deck as flagship drug faces competition
BioMarin Pharmaceutical Inc. is set to report second-quarter earnings, with analysts expecting 95 cents per share on $939.2 million in revenue, an increase from the previous quarter. The upcoming earnings call will likely focus on the competitive landscape for its top drug, VOXZOGO, which now faces rivalry from Ascendis Pharma's YUVIWEL. Investors will also monitor progress on recent acquisitions and the potential market expansion for VOXZOGO through a label extension for hypochondroplasia.
BioMarin Pharmaceutical Q2 Earnings Call Highlights
BioMarin Pharmaceutical's Q2 revenue approached $1 billion, a 20% increase year-over-year, driven by its rare-disease portfolio and the Amicus acquisition. The company raised its full-year guidance for revenue, VOXZOGO revenue, and non-GAAP EPS, projecting significant growth from Amicus therapies and VOXZOGO becoming a $1 billion product. Cost synergies from the Amicus acquisition are expected to be realized by 2028, making the deal earnings-accretive by 2027.
Molecule to Market: Agentifying the Pharma Value Chain
This article details an upcoming webinar titled "Molecule to Market: Agentifying the Pharma Value Chain" which will discuss how to overcome challenges in the pharmaceutical value chain by building an Enterprise AI Foundry for unified, AI-ready data. Speakers from BioMarin Pharmaceutical, Databricks, and Tredence will share insights on real architecture decisions, production use cases, measurable business outcomes, and the extension of data foundations into agentic workflows for R&D, supply chain, and commercial functions. The webinar aims to show how AI can move beyond insights to autonomous action in the pharma industry.
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
BioMarin Pharmaceutical Inc. announced that its President and CEO, Alexander Hardy, will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. ET. The call will discuss the company's second-quarter 2026 financial results and provide a general business update. Interested parties can access the live audio webcast through the investor section of BioMarin's website.
BioMarin Pharmaceutical Number of Employees 2026 | Employee Count & Headcount Data
This article provides an in-depth analysis of BioMarin Pharmaceutical's workforce data as of March 2026, sourced from Revelio Labs. It details the company's employee count (3,249), its 1.5% decline since 2023, and its active hiring with 363 job postings. The report also covers employee distribution by region and department, average salaries, and overall employee sentiment.
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
BioMarin Pharmaceutical Inc. will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to discuss its second-quarter 2026 financial results and provide a business update. Alexander Hardy, President and CEO, will lead the call. Interested parties can access the live audio webcast via the investor section of BioMarin's website, with a replay available for one week.
BioMarin CEO to Give Business Update in Aug. 6 Webcast
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that its President and CEO, Alexander Hardy, will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. ET. The event will cover the company's second-quarter 2026 financial results and provide a general business update. Investors can access the call via phone or live audio webcast through the investor section of BioMarin's website, with a replay available for one week.
BioMarin Pharmaceutical Inc (BMRN) Financial Health: Profitability & Balance Sheet Analysis
BioMarin Pharmaceutical Inc (BMRN) currently holds a robust financial score of 9.27, ranking 4th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company recently reported a 2.83% year-over-year increase in quarterly revenue, reaching $766.21 million, and a significant 43.17% rise in net profit. However, specific financial data for categories like cash and cash equivalents, total assets, and free cash flow have not yet been disclosed by the company.
H.C. Wainwright reiterates BioMarin stock rating at Neutral
H.C. Wainwright has reiterated a Neutral rating and $50.00 price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), despite the stock trading above this target and InvestingPro suggesting it is undervalued. The firm's renewed stance comes after the FDA published draft guidance describing a generic pathway for vosoritide, the active ingredient in BioMarin’s VOXZOGO, which could impact its long-term exclusivity. BioMarin also recently received FDA acceptance for its supplemental New Drug Application for full approval of VOXZOGO and presented positive three-year extension study data for the drug.
BioMarin Pharmaceutical Inc. Revenue Breakdown – NASDAQ:BMRN
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) generated $3.22 billion USD in revenue last year, primarily from its Innovative Therapies segment. This marks an increase from $2.85 billion USD in the previous year for the same segment. The United States was the largest geographical contributor, accounting for $1.10 billion USD of the company's total revenue.
Does BioMarin (BMRN) Expanding Into ReNU Syndrome Refine Its Rare Disease Pipeline Strategy?
BioMarin Pharmaceutical's collaboration with n-Lorem Foundation to develop an antisense oligonucleotide therapy for ReNU syndrome aligns with its strategy of focusing on high unmet-need rare diseases. While this early-stage program supports BioMarin's long-term pipeline, the near-term investment narrative remains dominated by VOXZOGO regulatory milestones and reimbursement pressures. The company projects significant revenue and earnings growth by 2029, suggesting a substantial upside to its current stock price according to some analysts.
How (BMRN) Movements Inform Risk Allocation Models
This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) providing AI-generated insights for risk allocation models. It highlights strong near-term sentiment but neutral mid and long-term outlooks, with no clear price positioning signal or resistance levels above the current price. The analysis includes specific institutional trading strategies like position trading, momentum breakout, and risk hedging, alongside a multi-timeframe signal analysis.
BioMarin and n-Lorem Foundation Enter Research Collaboration for ReNU Syndrome Treatment
BioMarin Pharmaceutical Inc. and n-Lorem Foundation have announced a partnership and global exclusive license agreement to develop the first antisense oligonucleotide (ASO) medicine for ReNU syndrome, a neurodevelopmental disorder identified in 2024. The collaboration focuses on an ASO candidate targeting the RNU4-2 (n.64_65insT) variant, which is believed to account for approximately 75% of ReNU syndrome cases. BioMarin will lead the broader development and commercialization efforts, expanding on n-Lorem's initial individualized approach for this ultra-rare condition, which is expected to affect around 100,000 individuals globally.
BioMarin Partners with n-Lorem to Develop Therapy for ReNU Syndrome
BioMarin Pharmaceutical is partnering with the n-Lorem Foundation to develop an antisense oligonucleotide therapy for ReNU syndrome, a rare neurodevelopmental genetic disorder. The therapy will target a specific gene variant believed to be responsible for 75% of ReNU cases. This collaboration, which includes joint preclinical studies and a shared decision on clinical trial candidates, aims to expedite research and significantly improve the quality of life for affected patients while expanding BioMarin's presence in the rare disease market.
